2371-31-5

Basic information

• Product Name: ASISCHEM Z49787
• Synonyms: ASISCHEM Z49787;CHEMBRDG-BB 5353323;2-[(4-chlorophenyl)amino]acetohydrazide
• CAS NO: 2371-31-5
• Molecular Formula: C₈H₁₀ClN₃O
• Molecular Weight: 199.64
• Mol File: 2371-31-5.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 486.7 °C at 760 mmHg
• Flash Point: 248.1 °C
• Appearance: /
• Density: 1.358 g/cm³
• Vapor Pressure: 1.26E-09mmHg at 25°C
• Refractive Index: 1.633
• CAS DataBase Reference: ASISCHEM Z49787(CAS DataBase Reference)
• NIST Chemistry Reference: ASISCHEM Z49787(2371-31-5)
• EPA Substance Registry System: ASISCHEM Z49787(2371-31-5)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 2371-31-5(Hazardous Substances Data)

Usage

Description

ASISCHEM Z49787, also known as 2-[(4-chlorophenyl)amino]acetohydrazide, is a chemical compound that serves as a versatile reactant and reagent in the synthesis of various organic compounds. Its unique structure and functional groups make it a valuable component in the development of new chemical entities for different applications.

Uses

Used in Pharmaceutical Industry:
ASISCHEM Z49787 is used as a reactant and reagent for the synthesis of various organic compounds, particularly in the development of new pharmaceuticals. Its ability to form a wide range of chemical entities makes it a promising candidate for creating novel drugs with potential therapeutic applications.
Used in Chemical Research:
In the field of chemical research, ASISCHEM Z49787 is utilized as a key building block for the synthesis of complex organic molecules. Its versatility in forming different chemical structures allows researchers to explore new avenues in chemical synthesis and potentially discover new compounds with unique properties and applications.
Used in Material Science:
ASISCHEM Z49787 can also be employed in the development of new materials with specific properties. Its involvement in the synthesis of various organic compounds can lead to the creation of materials with tailored characteristics, such as improved mechanical strength, thermal stability, or chemical resistance, depending on the desired application.

InChI:InChI=1/C8H10ClN3O/c9-6-1-3-7(4-2-6)11-5-8(13)12-10/h1-4,11H,5,10H2,(H,12,13)

Upstream product

• 404-25-1 N-(4-chlorophenyl)-2,2,2-trifluoroacetamide 
• 106-47-8 4-chloro-aniline 
• 5465-90-7 N-(4-chlorophenyl)glycine 
• 2521-89-3 ethyl 2-((4-chlorophenyl)amino)acetate 

Downstream Products

• 1489288-11-0 1-(4-chlorophenylaminoacetyl)-4-(4-phenylbenzyl)-thiosemicarbazide 
• 1311173-85-9 {2-(4-chlorophenyl)}-2,3,5a,6,11,11a-hexahydro-6,11-[1',2']-benzenobenzo[g]-1H-[1,2,4]triazino[1,2-b]phthalayine-4,5,12-trione 
• 1311173-82-6 2-[1-oxo-2-[(4-chlorophenyl)amino]-ethyl]-2,3,4a,5,10,10a-hexahydro-5,10-[1',2']-benzenobenzo[g]-phthalazine-1,4-dione 
• 1068709-16-9 (E)-N'-(3-bromo-4-fluorobenzylidene)-2-(4-chlorophenylamino)acetohydrazide 
• 142503-83-1 4-{3-[(4-Chloro-phenylamino)-methyl]-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazol-6-yl}-phenol 
• 142503-90-0 (4-Chloro-phenyl)-(6-p-tolyl-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazin-3-ylmethyl)-amine 
• 142503-82-0 (4-Chloro-phenyl)-(6-p-tolyl-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazol-3-ylmethyl)-amine 
• 142503-74-0 4-({(E)-3-[(4-Chloro-phenylamino)-methyl]-5-mercapto-[1,2,4]triazol-4-ylimino}-methyl)-phenol 
• 142503-89-7 (4-Chloro-phenyl)-(6-phenyl-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazin-3-ylmethyl)-amine 
• 142503-81-9 (4-Chloro-phenyl)-(6-phenyl-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazol-3-ylmethyl)-amine 
• 142503-73-9 5-[(4-Chloro-phenylamino)-methyl]-4-{[1-p-tolyl-meth-(E)-ylidene]-amino}-4H-[1,2,4]triazole-3-thiol 
• 142503-72-8 5-[(4-Chloro-phenylamino)-methyl]-4-{[1-phenyl-meth-(E)-ylidene]-amino}-4H-[1,2,4]triazole-3-thiol 
• 142503-67-1 3-(4-chloroanilinomethyl)-4-amino-5-mercapto-1,2,4-triazole 
• 93548-76-6 N-[3-Chloro-2-(3-nitro-phenyl)-4-oxo-azetidin-1-yl]-2-(4-chloro-phenylamino)-acetamide 

Relevant articles and documents

Design, Synthesis, and Evaluation of the Highly Selective and Potent G-Protein-Coupled Receptor Kinase 2 (GRK2) Inhibitor for the Potential Treatment of Heart Failure

A novel class of therapeutic drug candidates for heart failure, highly potent and selective GRK2 inhibitors, exhibit potentiation of β-adrenergic signaling in vitro studies. Hydrazone derivative 5 and 1,2,4-triazole derivative 24a were identified as hit compounds by HTS. New scaffold generation and SAR studies of all parts resulted in a 4-methyl-1,2,4-triazole derivative with an N-benzylcarboxamide moiety with highly potent activity toward GRK2 and selectivity over other kinases. In terms of subtype selectivity, these compounds showed enough selectivity against GRK1, 5, 6, and 7 with almost equipotent inhibition to GRK3. Our medicinal chemistry efforts led to the discovery of 115h (GRK2 IC50 = 18 nM), which was obtained the cocrystal structure with human GRK2 and an inhibitor of GRK2 that potentiates β-adrenergic receptor (βAR)-mediated cAMP accumulation and prevents internalization of βARs in β2AR-expressing HEK293 cells treated with isoproterenol. Therefore, 115h appears to be a novel class of therapeutic for heart failure treatment.

Aggrecanase-2 inhibitors based on the acylthiosemicarbazide zinc-binding group

Osteoarthritis is a disabling disease characterized by the articular cartilage breakdown. Aggrecanases are potential therapeutic targets for the treatment of this pathology. At the starting point of this project, an acylthiosemicarbazide was discovered to inhibit aggrecanase-2. The acylthiosemicarbazide Zn binding group is also a convenient linker for library synthesis. A focused library of 920 analogs was thus prepared and screened to establish structure-activity relationships. The modification of the acylthiosemicarbazide was also explored. This strategy combining library design and discrete compounds synthesis yielded inhibitor 35, that is highly selective for aggrecanases over a panel of metalloproteases and inhibits the degradation of native fully glycosylated aggrecan. A docking study generated binding conformations explaining the structure-activity relationships.

Synthesis, spectral studies and biological activities of some N-bridged heterocycles derived from 3-arylaminomethyl-4-amino-5-mercapto-1,2,4- triazoles

Synthesis of four 3-arylaminomethyl-4-amino-5-mercapto-1,2,4-triazoles starting from substituted anilines is described. These triazoles were employed in the synthesis of some N-bridged heterocycles carrying arylaminomethyl substituents. All the newly synthesized compounds were characterized by analytical, NMR and mass spectral studies. Some of the newly synthesized compounds were screened for their antibacterial and antiviral properties.